Specialize in novel and pragmatic approaches for designing clinical trials, and aim to transform the early-phase drug development with forward-looking vision and cutting-edge statistical methods.
We possess expertise in cancer genomics, computational biology, and bioinformatics.
We provide powerful precision medicine approaches to enable precise subgroup findings for clinical trial data.
Laiya provides advanced analytics models, including deep neural networks, machine learning, and Bayesian models for solving big/small data problems in health and non-health fields.
Clinical Trial Designs
Phase I Clinical Trial
- Single-Agent Dose-Finding Design
- Rapid Patient Enrollment
- Immune Oncology Trial Design
- Dose Cycle Dose-Finding Design
Phase I/II Clinical Trial
- Drug Combination Dose-Finding Design
- Adaptive Dose Insertion
- Phase I-II Seamless Design
- Multiple Cohort Expansion Design
Phase II Clinical Trial
- Subgroup Analysis and Enrichment Design
- Real World Data/Evidence Modeling and Design
- Customized trial designs for each client with computer simulations
- Simulation model tuning and simulation results analysis
- Generation of simulation results report
- Write up of the protocol statistical section based on simulation results report
- Draft of the protocol statistical section (Only for design related analysis)
- Cooperation with CRO, PI and sponsor to execute clinical trial designs
- Adaptive decision making based on interim data analysis
- Statistical analysis plan and study reports (Only for design related analysis)
- Go/No-Go decision
communication & training
- Communication with FDA, CDE, PI and sponsors
- Trainings on adaptive designs for the sponsors and CRO
- Statistical review of the protocol
- Review of clinical study report
- Adaptive randomization of patient enrollment
- Other adaptive processes, such as sample size re-estimation
LAIYA is an innovative and intelligent solution provider for new drug development. We specialize in Bayesian adaptive designs and implementation for drug and device clinical trials. Our mission is to develop the best-in-class adaptive designs, strategies, and integrated software platforms to lower the risk of clinical trial failure, improve the probability of success, accelerate the development process, and maximize portfolio returns.
Founded by a tenured professor of University of Chicago, Laiya has been a leading innovator in the application of Bayesian adaptive designs to clinical trials. Our team of world class Bayesian statisticians include PhDs from University of Texas, Fudan University and Rice University. Our work was published in top journals such as Nature Methods, Journal of Clinical Oncology, Journal of the National Cancer Institute, and has won several international awards:
- ISBA Mitchell Prize
- 1st Place Winner in the 2018 JSM Biopharmaceutical Section Student Paper Award
- Top 10 ideas in Precision Medicine Challenge organized by Harvard Business School
Laiya found wide recognition not only in the academic field but also in the industry. Many of its research initiatives have been developed into successful commercial products that were adopted by well-known global pharmaceutical companies, and FDA has approved clinical trial protocols incorporating these products.
U-Design is a web-based next-generation statistical and informatics tool kit for Phase I clinical trial design
The Bayesian early-phase seamless transformation (BEST) platform provides a fast, efficient, and powerful solution for early-phase drug development.
Modified Toxicity Probability Interval Design Version 2
Rolling Toxicity Probability Interval Design
Probability Interval Design based on both Toxicity and Efficacy
Multiple Doses/Multiple Indications Cohort Expansion
Dual-agent Drug Combination Dose Finding Design
Subgroup Cluster Based Bayesian Adaptive Design for Precision Medicine